MRI contrast agent enables early detection of liver disease

MRI contrast agent enables early detection of liver disease

• Download PDF Copy

By Sally Robertson, B.Sc.Oct 30 2019Reviewed by Kate Anderton, B.Sc. (Editor)

Researchers have developed a new MRI contrast dye that enables more accurate and safer detection of early-stage liver disease than currently approved agents. The new compound, called ProCA32.collagen1, was developed by scientists supported by the National Institute on Alcohol Abuse and Alcoholism, part of the NIH.